Aurora Cannabis Shoots For $512M Market: Marijuana Stock Analyst Initiates Coverage With Neutral
Aurora Cannabis (NASDAQ: ACB), a key player in the global medical marijuana market, stands at a strategic crossroads. Pablo Zuanic, a seasoned marijuana stock analyst from Zuanic & Associates, has initiated coverage on stock with a neutral rating. The core of his analysis hinges on whether Aurora’s push into international markets will bolster its future or accelerate its challenges.
Zuanic’s report delivers actionable insights into Aurora’s finances and strategy, equipping investors to interpret earnings, assess global market impacts and make informed decisions in a dynamic industry.
“ACB is among the two largest medical cannabis companies globally and stands to benefit significantly from nascent international markets, which we estimate could see a tenfold increase over the next decade,” Zuanic wrote.
Financial Overview
Zuanic’s report charts Aurora’s financial forecasts against its ambitious global expansion plans. Despite projecting a potential tenfold increase in international market size over the next decade, the analyst remains cautious.
He points out the company’s need to prove its growth strategies amid
an increasingly competitive and uncertain global landscape.
Aurora Cannabis reported FY24 sales at $270.3 million, with projections increasing to $355.3 million by FY27.
According to Zuanic, Aurora’s financial projections show significant improvements across key metrics over the next few years. The EPS (earnings per share) is forecasted to rise from -$0.12 in FY25 to $0.39 in FY27, indicating a turnaround from a loss per share to a profit per share, which suggests improving …